BPaLM regimen in India: A remarkable step towards tuberculosis elimination

India is having a high burden of drug-resistant tuberculosis. In a country with overwhelmed health facilities, it is a challenging task to address issues related to tuberculosis elimination. Further, India aims to achieve the global target of tuberculosis elimination by 2025, which is five years earlier than the global target. To achieve this uphill target, there is a constant need to improve the management of tuberculosis. One such latest development is the introduction of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM)-based regimens to fight against multidrug-resistant tuberculosis. The present article sheds light on this new treatment rolled out by the Government of India.